Ea4151-A Randomized Phase III Trial Of Consolidation With Autologous Hematopoietic Cell Transplantation Followed By Maintenance Rituximab Vs. Maintenance Rituximab Alone For Patients With Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Com
Posted Date: Mar 4, 2020
- Investigator: Tahir Latif
- Specialties: Cancer, Lymphoma, Oncology
- Type of Study: Drug
The primary goal of this study is to compare overall survival in MCL patients in MRD-negative first complete remission (CR) who undergo auto-HCT followed by maintenance rituximab vs. maintenance rituximab alone (without auto-HCT)
Criteria:
To Be Eligible: Must Have Confirmed Mantle Cell Lymphoma, 18-70 Yrs Of Age, No Cns Involvement Of Cancer, 4+ Cycles Of Induction Therapy, Complete Or Partial Remission, Ecog 0-2, No Other Malignancy Within 3 Years
Keywords:
Mantle Cell Lymphoma, Mlc, Cancer
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com